“I expect remdesivir with these variants will continue to make an impact on patients,” Gilead Sciences CEO Daniel O’Day told CNBC.
Source: Business - cnbc.com
“I expect remdesivir with these variants will continue to make an impact on patients,” Gilead Sciences CEO Daniel O’Day told CNBC.
Source: Business - cnbc.com